Clinical improvement in patients with ME/CFS with synergistic effect of Colchicine and Spironolactone..., 2022, do Campo et al

Full title:
CLINICAL IMPROVEMENT IN PATIENTS WITH ME/CFS WITH SYNERGISTIC EFFECT OF COLCHICINE AND SPIRONOLACTONE TARGETING INHIBITION OF INFLAMMASOME ACTIVITY

Dr Jorge do Campo1, Dr Vivienne Taylor2
1Noosa Hospital, Noosaville, Australia, 2Ibuki Medical Centre, Noosa, Australia
Background: Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) has been associated to Epstein Bar Virus (EBV), Coxsakie virus and Ross River virus infections. Recently a similar condition to ME/CFS has been described as ‘Long Covid’ associated to SARS-CoV-2.

Patients with positive EBV serology and ME/CFS may be carriers of a chronic latent infection that translates in a chronic systemic inflammation with neuroinflammation. The activation of the immunologic cascade after a viral infection or vaccination can trigger the formation of Anti-idiotype antibodies (Ab2) and an activation of pyrin domain containing protein3 (NRLP3) inflammasome. The NRLP3 inflammasome is the pattern of activation for interleukin (IL1-beta) cytokine complex which is activated in inflammatory conditions (1).

Colchicine is postulated to work by inhibiting tubulin polymerization and microtubule formation blocking inflammasome activation (2).

Spironolactone increased the activity and number of macrophage angiotensin converting enzyme 2 (ACE2) receptors. In the microglia this effect may represent a reduction of neuro-inflammation (3). In this abstract we present ME/CFS patients treated with the synergetic effect of Colchicine and Spironolactone to inhibit Inflammasome and decrease inflammation.

Population and Method: 23 patients (19 females) with positive serology for EBV infection and ME/CFS were included. All the patients were treated with multivitamins. Patients were educated about benefit and adverse effects of spironolactone and colchicine before treatment. The starting dose of Spironolactone was 12.5 mg a day increased to 25 mg a day (during years 2019 to 2021). The introduction of Colchicine 0.5 mg/day on treatment plan was during year 2021. Patient follow-up was in the outpatient clinic and GP clinic.

Results: Total 23 Patients 19 were Females age 37.3+28 and 4 were Males age 61+9. Two patients stop colchicine after 4 weeks. Improvement in cognitive skills was the early manifestation of spironolactone benefit. Patients reported to be less brain foggy, more alert, and they found it easier to focus when doing normal everyday activities.

They were also less irritable by noise and light and described themselves to be able to multi-task again. There was an improvement in general condition and everyday activities four weeks after Colchicine started.

Conclusion: Patients with ME/CFS improve their cognitive skills and everyday physical activity tolerance when treated with Colchicine and Spironolactone.

https://onlinelibrary.wiley.com/doi/10.1111/imj.23_15766

 

This hospital is less than two hours drive from me. Its too early to tell if this study is important, but it does look to be promising from the abstract. We need the full study to say more.

This is the third major news in the last week or so, involving either treatment or potential treatment. Even if this specific study turns out to be misleading this may be another sign things are turning around.

 

That would be disappointing indeed.

 

What is a "poster presentation" in this setting?

 

Colchicine is a mutagenic. When I used it in a science project it had to be in a fume cabinet so there is no way I am taking it for my ME without very, very strong evidence that it has a beneficial effect beyond patient report (questionnaires?)

 

Easiest just to link to this explanation, https://en.wikipedia.org/wiki/Poster_session